Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TNF | P01375 | 2/20 | 0.52 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.52 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3338089 | 0.90 | HTR6 (0.56) | HTR6CYP3A4CYP2D6TSHRMAPK1 | |
| SCHEMBL3339183 | 0.82 | HTR6 (0.65) | HTR6TSHRMAPK1LMNAALDH1A1 | |
| SCHEMBL3337520 | 0.81 | TSHR (0.55) | TSHRMAPK1LMNATNFNOD2 | |
| SCHEMBL5009048 | 0.78 | HTR6 (0.61) | HTR6TSHRMAPK1LMNATNF | |
| SCHEMBL5353003 | 0.77 | HTR6 (1.00) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL3342597 | 0.76 | ALDH1A1 (0.48) | HTR6TSHRMAPK1LMNATNF | |
| SCHEMBL5366543 | 0.76 | HTR6 (1.00) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL5103491 | 0.76 | HTR6 (0.61) | HTR6TSHRMAPK1LMNATNF | |
| SCHEMBL23217271 | 0.74 | TNF (0.80) | MAPK1LMNATNFNOD2NOD1 | |
| SCHEMBL5103514 | 0.73 | TSHR (0.53) | TSHRMAPK1LMNATNFNOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696229-B2 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-04-13 | — | — | US | claimed |
| EP-1984351-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | Memory Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | claimed |
| US-20080039462-A1 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION | 2008-02-14 | — | — | US | claimed |
| WO-2007098418-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-08-30 | — | — | WO | claimed |
| US-20100152177-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152177-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152177-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-7696229-B2 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696229-B2 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696229-B2 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-04-13 | — | — | US | disclosed |
| EP-1984351-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | Memory Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080039462-A1 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION | 2008-02-14 | — | — | US | disclosed |
| WO-2007098418-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152177-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR3B, HTR1B | HTR6 1/4885CYP3A4 567/4885CYP2D6 87/4885 |
| US-20080039462-A1 | Compounds having 5-HT6 receptor affinity | HTR6, HTR3B, HTR1B | HTR6 1/4885CYP3A4 567/4885CYP2D6 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.